<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04046315</url>
  </required_header>
  <id_info>
    <org_study_id>108818</org_study_id>
    <nct_id>NCT04046315</nct_id>
  </id_info>
  <brief_title>Early Detection of Cardiac Damage With CMR in Women With Breast Cancer</brief_title>
  <acronym>EARLY-CATCH</acronym>
  <official_title>Early Detection of Cardiac Damage With CMR in Women With Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      With this study the investigators will assess early cardiac damage by means of Global
      Longitudinal Strain (GLS) in newly diagnosed breast cancer (BC) patients treated with
      anthracycline-based chemotherapy, and to investigate whether myocardial damage as measured
      with T1 / T2 Cardiovascular Magnetic Resonance (CMR) mapping and plasma hs-Troponin T is
      related to changes in GLS.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Global Longitudinal Strain (GLS) change after chemotherapy compared to baseline</measure>
    <time_frame>Baseline and 2 weeks after the last chemotherapy cycle</time_frame>
    <description>A relative reduction in Global Longitudinal Strain (GLS) assessed with CMR</description>
  </primary_outcome>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Cardiotoxicity</condition>
  <condition>Breast Cancer</condition>
  <condition>Chemotherapy Induced Systolic Dysfunction</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>CMR</intervention_name>
    <description>GLS measurement with CMR</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will be recruited from the general BC population receiving (neo-)
        adjuvant chemotherapy. Patients with a new diagnosis of malignant neoplasm of the breast,
        codes C50.0-C50.9, according to the World Health Organization International Classification
        of Diseases (WHO-ICD) will be eligible for participation.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female

          -  Age â‰¥ 18 years

          -  A diagnosis of primary breast cancer

          -  Starting (neo-) adjuvant chemotherapy treatment within 2 months after screening

          -  Cardiotoxicity risk score of intermediate, high or very high risk

        Exclusion Criteria:

          -  Previous radiotherapy or systemic cancer treatment

          -  Cancer metastasis

          -  Life expectancy of less than 6 months

          -  History of myocardial infarction or heart failure

          -  Known contra-indications for CMR

          -  Refusal or inability to provide informed consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Saloua El Messaoudi, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Angela Maas, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robin Nijveldt, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yvonne Koop, MSc</last_name>
    <phone>+31 24-3616785</phone>
    <email>Yvonne.Koop@radboudumc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Radboud University Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yvonne Koop, MSc</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 1, 2019</study_first_submitted>
  <study_first_submitted_qc>August 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2019</study_first_posted>
  <last_update_submitted>March 12, 2020</last_update_submitted>
  <last_update_submitted_qc>March 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Cardiotoxicity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

